Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Earnings News For NBIX
-
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
-
Neurocrine: Q4 Earnings Snapshot
-
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
-
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
-
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
-
Neurocrine: Q3 Earnings Snapshot
-
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
-
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates
-
Neurocrine: Q2 Earnings Snapshot
-
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
-
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
-
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
-
Neurocrine: Q1 Earnings Snapshot
-
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
-
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
-
Neurocrine: Q4 Earnings Snapshot
-
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
-
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
-
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
-
Neurocrine: Q3 Earnings Snapshot
-
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
-
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
-
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates